DEA Telehealth Rules in 2026 for HRT Clinics

Current as of October 29, 2026. A US HRT clinic may prescribe testosterone after a telehealth visit without a prior in-person examination under a temporary DEA and HHS rule, if the rule’s conditions and all other applicable federal and state requirements are met. The temporary authorization ends at the close of December 31, 2026 unless the agencies change it. Testosterone is a federal Schedule III controlled substance, so the rule matters to TRT and other hormone practices that prescribe it. The same conclusion should not be applied automatically to every hormone therapy medication or every remote visit. [1][2][3]

The immediate operational answer is to use a live, two-way audio-video encounter for a new testosterone patient when relying on the 2026 flexibility; verify the prescriber’s authority and the patient’s location; document a legitimate medical purpose; and follow applicable state prescribing, monitoring, and electronic-prescribing rules. A proposed DEA special-registration system is not yet an active substitute for these checks. [2][3][4][5]

What the Ryan Haight Act normally requires

The Ryan Haight Online Pharmacy Consumer Protection Act amended the Controlled Substances Act to address controlled drugs dispensed by means of the Internet. Its general rule ties a valid prescription to at least one in-person medical evaluation by the prescribing practitioner, subject to defined exceptions, including qualifying practice of telemedicine. The law does not say that one in-person visit proves every later prescription is appropriate: each prescription still needs a legitimate medical purpose in the usual course of professional practice. [6]

For HRT clinics, the distinction is between the same practitioner who has already evaluated a patient in person and a practitioner who has never done so. DEA’s fourth-extension rule explains that, after an in-person evaluation by the prescribing practitioner, the Ryan Haight Act’s specific remote-prescribing restriction no longer applies to that practitioner–patient relationship. It does not create a universal waiver of state law, professional standards, DEA registration, or other prescription requirements. A prior visit with someone else in the same clinic should not be treated as automatically equivalent; another statutory exception would need its own analysis. [2][6]

During 2026, the temporary telemedicine rule supplies a separate path for a DEA-registered practitioner to prescribe Schedule II–V controlled substances to a patient the practitioner has not examined in person. That is the path many virtual TRT clinics need to assess. It applies only while its conditions are satisfied and only through December 31, 2026 as the regulation currently reads. [2]

What the temporary 2026 rule actually permits

Section 1307.41 of DEA’s regulations permits a DEA-registered practitioner to prescribe Schedule II–V controlled substances by telemedicine without a prior in-person evaluation during the rule’s effective period. It requires a legitimate medical purpose in the usual course of professional practice, a communication using the referenced interactive telecommunications system, authority under the practitioner’s registration or an applicable exemption for the drug, and a prescription that meets Part 1306. The federal rule preserves other applicable federal and state obligations. [2][7]

DEA describes the 2026 flexibility as allowing Schedule II–V prescribing through audio-video telemedicine. Its audio-only provision concerns specified FDA-approved Schedule III–V narcotic medications used for opioid use disorder; that is not a general phone-only route for testosterone. For a new testosterone patient, a clinic relying on this temporary rule should use a live, two-way video encounter. An online questionnaire, portal message, text exchange, or ordinary phone call should not be substituted for that encounter merely because the clinic calls the service “telehealth.” [3][4]

The extension changes the prior in-person evaluation requirement for qualifying encounters. It does not decide whether testosterone is clinically indicated, authorize a practitioner to prescribe outside their scope, grant a state license, or validate a prescription that lacks required information. A clinic must still evaluate the patient appropriately, record the basis for treatment, and issue each controlled prescription for a legitimate medical purpose. This article addresses workflow and law, not a testosterone treatment protocol. [2][7]

There is also a difference between the visit channel and the prescription channel. The 2026 telemedicine rule concerns the encounter and in-person evaluation. Electronic prescribing of controlled substances, when used, has its own DEA EPCS application, authentication, signature, transmission, and record requirements. DEA does not impose one nationwide rule that every controlled prescription must be electronic; state mandates and the separate CMS Part D measure may change a prescriber’s obligations. [7][8]

Does this cover testosterone and every HRT patient

Testosterone is explicitly listed in federal Schedule III. Therefore a testosterone prescription needs the controlled-substance analysis even when the rest of a patient’s hormone care is conducted virtually. Classify the actual medication being prescribed; “HRT,” “bioidentical,” and “compounded” are descriptions of care or formulation, not substitutes for checking the drug’s legal schedule and the prescriber’s authority. [1][7]

The current temporary rule does not set a special federal 30-day cap on a first remote testosterone prescription. Some readers may recall a 2023 DEA proposal that discussed a 30-day initial supply for certain non-narcotic Schedule III–V drugs. That proposal is not the operative 2026 rule. Do not build an ordering or refill workflow around a proposal as though it were binding law. Usual prescription requirements, state law, clinical judgment, and any pharmacy or payer constraints still matter. [2][9]

The rule also does not mean every video visit should produce a prescription. The clinician remains responsible for the assessment, clinical decision, monitoring plan, and follow-up under the standard of care. If a particular patient needs an in-person examination or procedure to evaluate safely, the federal telemedicine flexibility does not make that clinical step unnecessary. [2][7]

What is happening with DEA special registration

In January 2025, DEA proposed a special-registration framework for prescribing controlled substances by telemedicine without a prior in-person evaluation. The proposal described a Telemedicine Prescribing Registration for Schedule III–V, an advanced registration for some Schedule II–V prescribing, and a registration for certain telemedicine platforms. It also proposed limited state telemedicine registrations and additional recordkeeping and reporting. These details describe a notice of proposed rulemaking, not a registration route a TRT clinic can rely on today. [5]

As of October 29, 2026, the federal regulatory review site lists the special-registration rule at the final-rule review stage, with the review pending. A rule under review can change before publication and may have a later effective date. Do not tell a clinician that an application is available, that a proposed registration already replaces the in-person evaluation, or that the proposed requirements are final. A clinic should monitor the Federal Register and DEA’s telemedicine page, then update its workflow only from the published final text and effective date. [5][10]

The fourth temporary extension remains the operative general pathway for qualifying new-patient controlled-substance telemedicine prescribing through December 31, 2026. DEA and HHS have also issued separate final rules for particular buprenorphine treatment and Veterans Affairs situations. Those narrower rules should not be repackaged as a blanket testosterone rule for a private HRT clinic. [2][3]

Why state exemptions need a separate check

Federal permission is only one layer. A state may regulate professional licensure, controlled-substance authority, telehealth practice, patient consent, prescription-drug monitoring, electronic prescribing, and exceptions. The patient’s physical location at the time of the visit is therefore an essential scheduling and documentation fact. HHS notes that cross-state practice can depend on a full license, a compact, temporary practice law, reciprocity, or a state telehealth registration. None should be assumed available just because the patient lives there or the clinician is licensed somewhere else. [11]

California illustrates the licensing point. The Medical Board says a physician using telehealth to treat a patient located in California generally must hold a current California license, even if the physician lives elsewhere. It describes a limited out-of-state consultation exception that does not give the consulting physician ultimate authority over the California patient’s care. That exception is not a routine pathway for an out-of-state TRT prescriber to take over the patient’s treatment. California also expects the same standard of care and documented telehealth consent. [12]

Florida illustrates a different structure. Its 2026 telehealth statute allows a qualified out-of-state health professional to register for telehealth services to patients in Florida, subject to eligibility and practice limits. The same section restricts telehealth prescribing of Schedule II drugs to specified circumstances; testosterone’s federal Schedule III status means that particular Schedule II restriction is not the whole testosterone analysis. Florida also has narrow exceptions to its out-of-state telehealth registration requirement for an emergency medical condition or consultation with a Florida-licensed professional who retains ultimate authority. Neither the registration route nor those exceptions should be read as a blanket waiver of federal DEA registration or other Florida prescribing requirements. [1][13]

State electronic-prescribing exceptions are yet another question. A waiver from a state’s e-prescribing mandate does not, by itself, answer whether the prescriber may practice across state lines or whether the Ryan Haight Act’s in-person requirement is met. Label each claimed “exemption” by the exact rule it changes. Save the official source, the patient and prescriber jurisdictions, the clinician’s license type, and the date reviewed. Do not copy another state’s answer into a national policy. [2][8][11]

A workable telehealth prescribing checklist

For each proposed remote testosterone prescription, the clinic can run a short sequence before the clinician signs:

1. Identify the patient and location. Record where the patient is physically located during the encounter. If the patient has moved or is traveling, recheck the applicable state rules instead of relying on the home address alone. [11]
2. Verify the prescriber. Confirm the clinician’s active license, scope, state controlled-substance authority, DEA registration or applicable exemption, and the registration arrangement relevant to the patient and practice locations. The temporary in-person flexibility does not automatically provide these permissions. [2][7][14]
3. Select the legal visit path. Record whether the prescribing practitioner previously evaluated this patient in person or whether the clinic is relying on the 2026 temporary telemedicine rule or another defined exception. For the temporary path, use and document a live audio-video encounter. [2][3][6]
4. Document the medical decision. Preserve the encounter assessment and why the prescription has a legitimate medical purpose in the usual course of practice. Apply professional standards, state telehealth requirements, and any required prescription-monitoring checks. [2][7][11]
5. Create and sign the prescription correctly. Include the federal controlled-prescription elements; if transmitting electronically, use an EPCS application and the prescriber’s personal signing process. Check state electronic-prescribing and exception rules separately. [7][8]
6. Record the outcome. Confirm pharmacy transmission status, retain the required prescription and audit records, and investigate failed delivery before sending a replacement. Build a lawful outage route rather than assuming a printable screen is a valid fallback. [7][8]

The checklist is a control for clinic staff, not a substitute for the clinician’s judgment. It is most useful when attached to a sample patient journey in a vendor demonstration. Ask the EMR and EPCS providers to show where location, prescriber authority, modality, signed prescription, and failed-transmission status appear in the actual configuration proposed for your clinic. Do not infer that a general telehealth feature enforces controlled-substance rules automatically. [2][7][8]

Three scenarios HRT clinics should distinguish

New virtual patient, no prior in-person visit with the prescriber. In 2026, the clinician may consider the temporary pathway if all of section 1307.41’s conditions and applicable state requirements are met. Use live audio-video for a testosterone encounter under that pathway. A phone intake plus an asynchronous questionnaire is not the same encounter. [2][3]

Established patient previously examined in person by the same prescriber. The Ryan Haight Act’s specific prior-exam barrier is different for this relationship, but each new prescription still requires a legitimate medical purpose and compliance with DEA, state, and professional rules. Do not promise that future in-person care is never clinically necessary. [2][6]

Patient joins a video visit from another state. Pause and verify the new patient location, clinician’s authority there, DEA registration position, and that state’s telehealth and prescribing rules. A software account enabled for multiple states or a state telehealth registration alone does not establish every required authority. [11][14]

What to plan before December 31, 2026

The current regulation sets an end date, not a guarantee about what takes effect on January 1, 2027. A clinic should inventory patients whose testosterone prescribing currently depends on the no-prior-in-person temporary path, identify the responsible prescriber and patient state, and flag upcoming visits and prescription dates. The clinic should also map how an in-person evaluation could be arranged if the applicable legal route changes. Do not create a blanket appointment requirement from a proposal; plan capacity while waiting for binding text. [2][5][10]

Assign one owner to check the Federal Register and DEA updates, record the rule and effective date, and revise scheduling, consent, prescribing, and patient communications once there is a published change. Keep those legal decisions separate from EMR configuration. For WealMD, use a demonstration to test patient-location capture, video workflow, documentation, EPCS handoff, and exportable records in the version offered to your clinic. Ask the product team to identify any third-party service and show the evidence for each claimed controlled-prescribing capability. [2][7][8]

For related reading, see WealMD’s EPCS guide for HRT clinics and the testosterone EPCS practitioner guide. To walk through your own clinic scenario, book a WealMD demo.

Frequently asked questions

Can a TRT clinic start testosterone by telehealth in 2026 without an in-person visit

Potentially. Under the current temporary federal rule, a properly authorized practitioner may prescribe a Schedule III drug without first examining the patient in person if the rule’s conditions are met. For a testosterone visit under that pathway, use live audio-video and verify state law, registration, and the clinical basis for the prescription. The temporary rule expires at the end of December 31, 2026 as currently written. [1][2][3]

Is a phone call enough for a new testosterone prescription

Do not rely on a routine audio-only call for the testosterone pathway in DEA’s 2026 extension. DEA’s described audio-only exception concerns specified opioid-use-disorder medication, not testosterone. Use a live two-way video encounter when relying on this temporary rule. [3]

Is the DEA special registration available now

As of October 29, 2026, the 2025 special-registration proposal is under final-rule review, with no published final rule that would make the proposed framework operative. Recheck DEA and the Federal Register before changing practice. [5][10]

Does a state telehealth registration replace a DEA registration

No automatic substitution follows from a state telehealth registration. They address different authorities. Verify the clinician’s state professional and controlled-substance authority plus the applicable DEA registration or exemption for the real practice arrangement. [11][13][14]

Sources

1. eCFR, 21 CFR 1308.13, Schedule III, current text. Official source
2. eCFR, 21 CFR 1307.41, temporary telemedicine flexibilities, current text. Official source
3. DEA, Fourth Temporary Extension press release, December 31, 2025. Official source
4. HHS, Prescribing controlled substances via telehealth, January 2026. Official source
5. Federal Register, Special Registrations for Telemedicine and Limited State Telemedicine Registrations, proposed rule, January 17, 2025. Official source
6. US Code, 21 USC 829(e), controlled substances dispensed by means of the Internet. Official source
7. eCFR, 21 CFR Part 1306, prescriptions, current text. Official source
8. eCFR, 21 CFR Part 1311, electronic prescriptions, current text. Official source
9. DEA, Proposed Telemedicine Rules Summary, February 2023. Official source
10. OMB Office of Information and Regulatory Affairs, pending review of RIN 1117-AB40, accessed October 29, 2026. Official source
11. HHS, Licensing across state lines, April 2025. Official source
12. Medical Board of California, Telehealth. Official source
13. Florida Legislature, 2026 Florida Statutes, section 456.47. Official source
14. eCFR, 21 CFR 1301.12, separate registrations for separate locations, current text. Official source